{"id":42312,"date":"2018-07-20T19:34:00","date_gmt":"2018-07-20T17:34:00","guid":{"rendered":"https:\/\/newserver.fyb.de\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/"},"modified":"2018-07-20T19:34:00","modified_gmt":"2018-07-20T17:34:00","slug":"first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/","title":{"rendered":"First closing at medtech investor SHS: over 90 million euros for Fund&nbsp;V"},"content":{"rendered":"<p>T\u00fcbin\u00adgen -<strong> SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment<\/strong> has recei\u00adved capi\u00adtal commit\u00adments of more than EUR 90 million for its now fifth fund at the so-called \u201cfirst closing\u201d. The T\u00fcbin\u00adgen-based medi\u00adcal tech\u00adno\u00adlogy inves\u00adtor has thus reached almost two-thirds of its <strong>target of 150 million euros<\/strong> faster than expected.<\/p>\n<p>The fifth gene\u00adra\u00adtion of SHS funds also targets the life scien\u00adces and medi\u00adcal tech\u00adno\u00adlogy sectors and thus the globally growing health\u00adcare market with inno\u00adva\u00adtive and strong compa\u00adnies, espe\u00adci\u00adally in Germany and Switz\u00ader\u00adland. 12\u201315 enga\u00adge\u00adments are plan\u00adned. With the \u201cfirst closing\u201d, fund compa\u00adnies complete an initial capi\u00adtal coll\u00adec\u00adtion phase \u2014 usually when half of the total target volume has been reached. With the formal comple\u00adtion of this first phase, the capi\u00adtal coll\u00adec\u00adted can alre\u00adady be inves\u00adted in compa\u00adnies. Inves\u00adtors can still parti\u00adci\u00adpate in SHS V until the \u201cfinal closing\u201d. Around half of the inves\u00adtors in SHS V had alre\u00adady parti\u00adci\u00adpa\u00adted in the T\u00fcbin\u00adgen-based company\u2019s prede\u00adces\u00adsor&nbsp;funds.<\/p>\n<p>SHS attri\u00adbu\u00adtes the strong demand from insti\u00adtu\u00adtio\u00adnal inves\u00adtors and family offices to its posi\u00adtio\u00adning as a <strong>sector specia\u00adlist<\/strong>. \u201cWe would like to thank the inves\u00adtors for their trust. For 25 years on the market, we have focu\u00adsed on invest\u00adments in compa\u00adnies from the medi\u00adcal tech\u00adno\u00adlogy and diagno\u00adstics sectors. We have built up a great deal of indus\u00adtry expe\u00adri\u00adence and trust, and also have the neces\u00adsary intui\u00adtion for feasi\u00adble inno\u00adva\u00adtions. Our port\u00adfo\u00adlio compa\u00adnies can build on an estab\u00adlished network of indus\u00adtry experts, health insu\u00adr\u00aders and medi\u00adcal opinion leaders. In addi\u00adtion, we support the compa\u00adnies\u2019 value deve\u00adlo\u00adp\u00adment with inter\u00adna\u00adtio\u00adna\u00adliza\u00adtion know-how as well as exper\u00adtise in reim\u00adbur\u00adse\u00adment and regu\u00adla\u00adtory issues and in initia\u00adting stra\u00adte\u00adgic part\u00adner\u00adships,\u201d says  <strong>Huber\u00adtus Leon\u00adhardt, SHS part\u00adner and mana\u00adging direc\u00adtor<\/strong> respon\u00adsi\u00adble for fundraising.<\/p>\n<p><strong>Focus on expan\u00adsion finan\u00adcing and corpo\u00adrate successions<\/strong><br>\nMini\u00admally inva\u00adsive surgi\u00adcal proce\u00addu\u00adres, robo\u00adtics-supported forms of therapy and digi\u00adtal solu\u00adti\u00adons for the health\u00adcare sector are seen as parti\u00adcu\u00adlarly inno\u00adva\u00adtive and fast-growing fields in T\u00fcbin\u00adgen. Indus\u00adtrial exper\u00adtise, the avai\u00adla\u00adbi\u00adlity of well-trai\u00adned engi\u00adneers, and above all the close links between the univer\u00adsity and rese\u00adarch land\u00adscape and indus\u00adtry have crea\u00adted a good climate in the indus\u00adtry in Germany and Switzerland.<\/p>\n<p>\u201cWe alre\u00adady see a large number of fast-growing health\u00adcare compa\u00adnies, both young and estab\u00adlished, in which our fifth fund could invest. Tigh\u00adter regu\u00adla\u00adtion and high pres\u00adsure to inno\u00advate and inter\u00adna\u00adtio\u00adna\u00adlize are leading to incre\u00adasing demand for capi\u00adtal in the sector. The incre\u00adasing comple\u00adxity of the health\u00adcare market is driving concen\u00adtra\u00adtion proces\u00adses. In addi\u00adtion, some compa\u00adnies are strugg\u00adling to ensure a successful hando\u00adver to the next gene\u00adra\u00adtion. As an expe\u00adri\u00aden\u00adced part\u00adner, we can provide compa\u00adnies with targe\u00adted and compe\u00adtent support here,\u201d says Leonhardt.<\/p>\n<p>Accor\u00adding to SHS, the maxi\u00admum invest\u00adment amount of the fifth fund per invest\u00adment is 30 million euros. Toge\u00adther with coope\u00adra\u00adtion part\u00adners, equity tran\u00adsac\u00adtions of up to EUR 60 million can be carried out. Majo\u00adrity and mino\u00adrity share\u00adhol\u00addings are possi\u00adble. The focus is on expan\u00adsion and inno\u00adva\u00adtion finan\u00adcing, succes\u00adsion situa\u00adtions and share\u00adhol\u00adder chan\u00adges. SHS is expan\u00adding its previous coun\u00adtry focus on Germany, Austria and Switz\u00ader\u00adland to include Scan\u00addi\u00adna\u00advia and the Bene\u00adlux count\u00adries. SHS had contri\u00adbu\u00adted capi\u00adtal, many years of exper\u00adtise, market know\u00adledge and its network to the Fonds IV invest\u00adments \u2014 such as EIT, a 3D prin\u00adting specia\u00adlist for the ortho\u00adpe\u00addics sector, the Austrian robo\u00adtics company Tyro\u00admo\u00adtion, which is active in the reha\u00adbi\u00adli\u00adta\u00adtion sector, and the Swiss manu\u00adfac\u00adtu\u00adrer of cardio\u00adlogy products SIS Medical.<\/p>\n<p>With invest\u00adments from the SHS III fund, for exam\u00adple, the Bochum-based company phenox, which specia\u00adli\u00adzes in tech\u00adno\u00adlo\u00adgies for the treat\u00adment of neuro\u00advas\u00adcu\u00adlar dise\u00ada\u00adses, was successfully deve\u00adlo\u00adped. SHS recently announ\u00adced the sale of its SHS III invest\u00adment AMW, a Warn\u00adgau-based specia\u00adlist in drug deli\u00advery systems, to an inter\u00adna\u00adtio\u00adnal strategist.<\/p>\n<p><strong>About SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment&nbsp;mbH<\/strong><br>\nT\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment invests in medi\u00adcal tech\u00adno\u00adlogy and life science compa\u00adnies with a focus on expan\u00adsion finan\u00adcing, share\u00adhol\u00adder chan\u00adges and succes\u00adsion situa\u00adtions. In doing so, SHS enters into both mino\u00adrity and majo\u00adrity share\u00adhol\u00addings. As an expe\u00adri\u00aden\u00adced indus\u00adtry inves\u00adtor, SHS, which was foun\u00added in 1993, supports the growth of its port\u00adfo\u00adlio compa\u00adnies through a network of colla\u00adbo\u00adra\u00adti\u00adons, for exam\u00adple in the intro\u00adduc\u00adtion of new products, regu\u00adla\u00adtory issues or entry into addi\u00adtio\u00adnal markets.<\/p>\n<p>German and inter\u00adna\u00adtio\u00adnal inves\u00adtors in SHS funds include the Euro\u00adpean Invest\u00adment Fund, profes\u00adsio\u00adnal pension funds, pension funds, funds of funds, family offices, entre\u00adpre\u00adneurs and the SHS manage\u00adment team. The equity invest\u00adment of the AIFM-regis\u00adtered company is up to 30 million euros. Tran\u00adsac\u00adtions in the mid double-digit million range can be imple\u00admen\u00adted toge\u00adther with a network of co-inves\u00adtors. Mana\u00adging part\u00adners at SHS are Rein\u00adhilde Spat\u00adscheck, Dr. Bern\u00adhard Schirm\u00aders, Huber\u00adtus Leon\u00adhardt and Uwe Steinbacher.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>T\u00fcbin\u00adgen \u2014 SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment has recei\u00adved capi\u00adtal commit\u00adments of more than EUR 90 million for its now fifth fund at the so-called \u201cfirst closing\u201d. The T\u00fcbin\u00ad\u00adgen-based medi\u00adcal tech\u00adno\u00adlogy inves\u00adtor has thus reached almost two-thirds of its target of 150 million euros faster than expec\u00adted. The fifth gene\u00adra\u00adtion of SHS funds also targets the&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"T\u00fcbin\u00adgen - SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment has recei\u00adved capi\u00adtal commit\u00adments of more than EUR 90 million for its now fifth fund at the so-called \u201cfirst closing\u201d. The T\u00fcbin\u00adgen-based medi\u00adcal tech\u00adno\u00adlogy inves\u00adtor has thus reached almost two-thirds of its target of 150 million euros faster than expected. The fifth gene\u00adra\u00adtion of SHS funds also targets the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-20T17:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"First closing at medtech investor SHS: over 90 million euros for Fund&nbsp;V\",\"datePublished\":\"2018-07-20T17:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\"},\"wordCount\":756,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\",\"url\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\",\"name\":\"First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png\",\"datePublished\":\"2018-07-20T17:34:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png\",\"width\":300,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First closing at medtech investor SHS: over 90 million euros for Fund&nbsp;V\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/","og_locale":"en_US","og_type":"article","og_title":"First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook","og_description":"T\u00fcbin\u00adgen - SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment has recei\u00adved capi\u00adtal commit\u00adments of more than EUR 90 million for its now fifth fund at the so-called \u201cfirst closing\u201d. The T\u00fcbin\u00adgen-based medi\u00adcal tech\u00adno\u00adlogy inves\u00adtor has thus reached almost two-thirds of its target of 150 million euros faster than expected. The fifth gene\u00adra\u00adtion of SHS funds also targets the [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-07-20T17:34:00+00:00","og_image":[{"width":300,"height":200,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"First closing at medtech investor SHS: over 90 million euros for Fund&nbsp;V","datePublished":"2018-07-20T17:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/"},"wordCount":756,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/","url":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/","name":"First closing at medtech investor SHS: over 90 million euros for Fund V - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png","datePublished":"2018-07-20T17:34:00+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/07\/a-shs-2.png","width":300,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/first-closing-at-medtech-investor-shs-over-90-million-euros-for-fund-v\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"First closing at medtech investor SHS: over 90 million euros for Fund&nbsp;V"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42312"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42324"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}